L-Carnitine vs Retatrutide
A side-by-side research comparison of L-Carnitine and Retatrutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | L-Carnitine | Retatrutide |
|---|---|---|
| Full name | L-Carnitine Injectable | Retatrutide (Triple Agonist GIP/GLP-1/Glucagon) |
| Category | Weight Management | Weight Management |
| Status | Supplement / Compounded | Phase 3 Clinical Trial |
| Mechanism | Transports long-chain fatty acids across the inner mitochondrial membrane via the carnitine shuttle, enabling beta-oxidation for ATP production. Also reduces oxidative stress and supports cardiac function. | Triple agonism creates synergistic metabolic effects. Glucagon activation increases energy expenditure and hepatic fat oxidation while GLP-1/GIP reduce appetite and improve insulin sensitivity. |
| Molecular weight | 161.20 Da | 5,200 Da (approximate) |
| Half-life | ~2-3 hours (IM) | 6 days |
| Bioavailability | ~100% injectable; ~14-18% oral | High (SubQ) |
| Typical dose | 500-2000 mg | 1-2 mg → titrate up to 12 mg |
| Frequency | 2-5x per week | Once weekly |
| Route | Intramuscular or IV injection | Subcutaneous injection |
L-Carnitine reported benefits
- Enhanced fat oxidation
- Improved energy
- Exercise performance
- Cardiac health
- Recovery support
- Mitochondrial function
Retatrutide reported benefits
- Unprecedented weight loss (~24%)
- Significant liver fat reduction
- Improved cardiovascular markers
- Enhanced energy expenditure
- Superior glycemic control
Related comparisons
Research and educational reference only. Not medical advice.